Therapy (HCV)
PEG-INTRON A Advances To Phase III Clinical Trials
Published in Cancer Weekly, August 18th, 1997
PEG-INTRON A is a modified form of Schering-Plough's INTRON A (interferon alfa-2b, recombinant), developed by Enzon to have longer-acting properties. In this Phase III program, PEG-INTRON A administered once a week, is compared to INTRON A at the licensed regimen, which is currently three times a week. Enzon currently has two U.S. Food and Drug Administration approved products on the market that use this PEG Modification technology.
INTRON A...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (1997-08-18)
More Articles from Cancer Weekly
- Cancer Vaccines (Clinical Trial)
Active Immunization with IL-2-Transduced Allogeneic Melanoma Cells - Breast Cancer
Breast Cancer is No. 1 Cause of Cancer-Related Deaths in African Women - Breast Cancer
Delegation Joined 650 People from 54 Countries for World Cancer Conference - Breast Cancer (Risk Factors)
Increased Rates in Hawaii may be Linked to Pesticides - Breast Cancer (Risk Factors)
Patients Have No Extra Risk from Pregnancy - Breast Cancer (TSG101Gene)
Second Look Acquits Gene Of Role In Breast Cancer - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
